Pharmacology
FDA Approves High Dose Kadian(R) for Severe Chronic Pain
By Alpharma Inc.
May 6, 2005, 10:13

Alpharma Inc. (NYSE: ALO),a leading global generic pharmaceutical company, today announced that it has been notified by United States Food and Drug Administration that its pending application for Kadian(R) 200mg capsule has received approvable status.

Kadian(R) is Alpharma's branded sustained release morphine sulfate product and is currently marketed in 20mg, 30mg, 50mg, 60mg and 100mg dosages. The company plans to launch the new dosage form following final FDA approval.

"We are extremely pleased to receive approvable status on this important new higher dosage of Kadian(R) which will help meet the needs of some the most severe sufferers of chronic pain," commented Ronald Warner, PhD, President of
Alpharma's Branded Products business. "Kadian(R) already has a significant advantage over competitive products as a result of the dosing flexibility it offers physicians and their patients and is the only brand in its category
that can be dosed either once or twice daily. This added dosage form, which will be marketed by our recently expanded sales force, will help physicians individualize their patients treatments by offering more choices in managing their pain."

All rights reserved by www.rxpgnews.com